+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetes Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

  • PDF Icon

    Report

  • 120 Pages
  • June 2024
  • Region: Global
  • GlobalData
  • ID: 5823110
The analyst's Medical Devices sector report, “Diabetes Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Diabetes Assays pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Diabetes Assays are tests to first diagnose diabetes and assess the risk of diabetes, such as pre-diabetes, through analysis of blood.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Diabetes Assays under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Diabetes Assays and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to :

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Diabetes Assays under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Diabetes Assays Overview
3 Products under Development
3.1 Diabetes Assays - Pipeline Products by Stage of Development
3.2 Diabetes Assays - Pipeline Products by Segment
3.3 Diabetes Assays - Pipeline Products by Territory
3.4 Diabetes Assays - Pipeline Products by Regulatory Path
3.5 Diabetes Assays - Pipeline Products by Estimated Approval Date
4 Diabetes Assays - Pipeline Products under Development by Companies
4.1 Diabetes Assays Companies - Pipeline Products by Stage of Development
4.2 Diabetes Assays - Pipeline Products by Stage of Development
5 Diabetes Assays Companies and Product Overview
6 Diabetes Assays- Recent Developments
6.1 May 15, 2024: Advanced Screening Method for Early Detection of Type 1 Diabetes Exceeds Traditional Standards
6.2 Feb 21, 2024: World-First Introduction of Home Oral Glucose Tolerance Testing Service for Gestational Diabetes Sees University Hospital Southampton Improve Test Accessibility and Yield Maximum User Preference Scores
6.3 Feb 06, 2024: Beckman Coulter Diagnostics Appoints Kevin O'Reilly as New President
6.4 Jan 23, 2024: Enable Biosciences Enhances ‘Kit to Clinics’ With Rigorously Vetted Adap Technology for Diabetes Care
6.5 Jan 10, 2024: A New Study Shows Glycomark is a Novel Biomarker of SGLT-2I Adherence
6.6 Dec 19, 2023: Enable Biosciences Receives $3M Phase IIB SBIR Award From NIDDK for Advanced T1D Testing Technology
6.7 Nov 30, 2023: Switch Health develops Canada’s first at-home diagnostic Diabetes test
6.8 Nov 17, 2023: New Research Center for Artificial Intelligence and Causal Methods in Medicine
6.9 Oct 30, 2023: New Clinical Data Point To Use of Glycomark as Biomarker of Sglt-2 Diabetes Drug Effectiveness and Compliance
6.10 Oct 19, 2023: Abbott Diagnostics Obtains Additional 510(k) Clearance for Afinion HbA1c Test
7 Appendix
7.1 Methodology
7.2 About the Analyst
7.3 Contact the Publisher
7.4 Disclaimer
List of Tables
  • Diabetes Assays - Pipeline Products by Stage of Development
  • Diabetes Assays - Pipeline Products by Segment
  • Diabetes Assays - Pipeline Products by Territory
  • Diabetes Assays - Pipeline Products by Regulatory Path
  • Diabetes Assays - Pipeline Products by Estimated Approval Date
  • Diabetes Assays Companies - Pipeline Products by Stage of Development
  • Diabetes Assays - Pipeline Products by Stage of Development
  • Glossary
List of Figures
  • Diabetes Assays - Pipeline Products by Stage of Development
  • Diabetes Assays - Pipeline Products by Segment
  • Diabetes Assays - Pipeline Products by Territory
  • Diabetes Assays - Pipeline Products by Regulatory Path
  • Diabetes Assays - Pipeline Products by Estimated Approval Date

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 1Drop Diagnostics
  • Abcodia Ltd
  • Abionic SA
  • Adaptive Biotechnologies Corp
  • Adipomics Inc
  • Aditxt Inc
  • Advanced Genetic Diagnostics Pty Ltd
  • Alfa Wassermann Inc
  • AmideBio, LLC
  • Aura Biotechnologies Pvt Ltd
  • Beckman Coulter Inc
  • Biocrates Life Sciences AG
  • BioDesign Institute at Arizona State University
  • Biogenes Technologies Sdn Bhd
  • Biomorph Technologies LLC
  • CellCarta Precision Medicine Inc
  • Confer Health Inc
  • Drexel University
  • Dx&Vx
  • Electronic BioSciences Inc.
  • Enable Biosciences Inc
  • FibroStatin SL
  • G Medical Innovations Holdings Ltd
  • GATC DB Care Corp
  • Gelteq Ltd
  • Genesis Detection Systems, Inc.
  • Guangzhou Wondfo Biotech Co Ltd
  • Helmholtz Centre for Infection Research
  • Hemex Health Inc
  • Human Cell Design SAS
  • Interpace Biosciences Inc
  • IntraMed Diagnostics, LLC
  • Janssen Diagnostics LLC
  • Johns Hopkins University
  • L2 Diagnostics LLC
  • Matter Diagnostics
  • MediSure Canada Inc
  • Mellitus LLC
  • MultiOmic Health Ltd
  • Numares AG
  • Peri Rx Inc
  • Phaim Pharma Ltd
  • Phase Scientific International Ltd
  • PortaScience Inc
  • Precision Diabetes LLC
  • Protagen AG
  • QSTAG Co Ltd
  • Queen Mary University of London
  • QuickCheck Health Inc
  • Sebia
  • Sera Prognostics Inc
  • Singulex Inc
  • SomaLogic Inc
  • SpinChip Diagnostics AS
  • Stanford University
  • Sugentech Inc
  • Tetz Laboratories
  • The Forsyth Institute
  • University of Canterbury
  • University of Colorado
  • University of Florida
  • University of Newcastle
  • University of Oxford
  • University of South Florida
  • University of Strathclyde
  • Vactech Oy
  • Vital Diagnostics, Inc. (Inactive)
  • Wave 80 Biosciences Inc
  • Xhale Inc
  • Yaathum Biotech Pvt Ltd
  • Yale University